Vimta Labs Limited — PPTs, 28-04-2025: Investor Presentation

**Financial Highlights:**

In Q4, total income reached ₹961 Mn, with a profit after tax (PAT) of ₹183 Mn and a profit margin of 19.1%. EBITDA stood at ₹347 Mn, reflecting a margin of 36.1%. For FY25, total income amounted to ₹3,482 Mn, with PAT rising to ₹668 Mn and an overall margin of 19.2%. EBITDA for FY25 was ₹1,262 Mn, achieving a margin of 36.2%. The company's debt-to-equity ratio remains low at 0.02x, with cash and cash equivalents positioned at ₹329 Mn.

**Strategic Initiatives & Growth Drivers:**

Vimta has expanded its capacity for clinical trial services by adding 200,000 sq. ft. of laboratory space and relocated its Pune food testing lab to Nashik to enhance accessibility to agricultural regions. The successful merger of EMTAC with Vimta marks a strategic move into broader service offerings.

**Business Developments:**

Vimta completed regulatory audits from various authorities, bolstering its operational credibility. The food division received the 'Outstanding Laboratory Performance Award 2024', and a business transfer agreement was established with Thyrocare, enhancing its service capabilities.

**Market Position & Competitive Advantage:**

As a leading CRO in India, Vimta derives approximately 75% of its revenue from overseas markets. The company has strong partnerships with major players in the food testing sector and holds a significant position in clinical research and electronics testing.

**Investor Implications:**

These updates indicate positive growth potential for investors, propelled by strategic expansions and operational enhancements, although execution risk warrants close monitoring.